Non-Incretin Class Obesity Drug Candidate
Upfront Payment of $190 Million

Hanmi Pharmaceutical has licensed its independently developed non-incretin obesity drug candidate, HM17321 (a UCN2 analog), to Genentech, a member of the Roche Group. The contract is valued at up to $2.3 billion (approximately KRW 3.5 trillion), including an upfront payment of $190 million (KRW 262 billion), making it the largest deal for a single drug candidate since Hanmi Pharmaceutical's major out-licensing agreements in 2015.


On August 24, Hanmi Pharmaceutical announced that it has signed an exclusive license agreement with Genentech for HM17321, aimed at treating metabolic diseases such as obesity, type 2 diabetes, and cardiovascular disorders.

Hanmi Pharmaceutical Headquarters. Hanmi Pharmaceutical

Hanmi Pharmaceutical Headquarters. Hanmi Pharmaceutical

View original image

Under the terms of the agreement, Genentech will secure exclusive rights to develop, manufacture, and commercialize HM17321 worldwide except in Korea. Hanmi Pharmaceutical plans to transfer development of the compound to Genentech from Phase 2 clinical trials onward, upon completion of the ongoing Phase 1 trial.


HM17321 is a non-incretin UCN2 (Urocortin-2) analog drug candidate independently developed by Hanmi Pharmaceutical. The company is developing it as a first-in-class drug designed to simultaneously achieve weight loss and muscle preservation.


The currently available GLP-1-based incretin class obesity treatments have demonstrated powerful weight loss effects, but have faced criticism for also causing reductions in lean body mass during treatment. HM17321 is designed to overcome these limitations by targeting both weight loss and body composition improvement.


Nonclinical studies have confirmed that HM17321, when administered alone or in combination with GLP-1 class therapies, delivers both weight loss and improvement in body composition. As a peptide-based therapy, the compound holds potential for future development as a fixed-dose combination (FDC) or a combination therapy with incretin-based drugs.


In November 2025, Hanmi Pharmaceutical received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for a Phase 1 clinical trial of HM17321. The company is currently conducting Phase 1 clinical trials evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of HM17321 in healthy adults and obese patients.


Under the terms of this agreement, Hanmi Pharmaceutical will receive an upfront payment of $190 million (approximately KRW 285 billion) from Genentech. The total contract size, including clinical development, regulatory approvals, and commercialization milestones, may reach up to $2.3 billion. Hanmi Pharmaceutical will also receive royalties following product launch.


Choi Inyoung, Executive Vice President and Head of Future Growth at Hanmi Pharmaceutical, stated, "The paradigm of obesity treatment is evolving beyond simple weight loss to improving body composition and restoring metabolic health. We believe it is significant that the differentiated scientific mechanism and development potential of HM17321 have been recognized in the global market."



Boris L. Zeitler, Global Head of Business Development at Roche, said, "By introducing this next-generation first-in-class candidate from Hanmi Pharmaceutical, Roche and Genentech plan to pursue a differentiated therapeutic strategy that selectively reduces fat mass while improving muscle mass and function."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing